Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

L H Sehn, N Chua, J Mayer, G Dueck, M Trneny, K Bouabdallah, N Fowler, V Delwail, O Press, G Salles, J Gribben, A Lennard, Elly Lugtenburg, N Dimier, E Wassner-Fritsch, G Fingerle-Rowson, BD Cheson

Research output: Contribution to journalArticleAcademicpeer-review

265 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)1081-1093
Number of pages13
JournalLancet Oncology
Issue number8
Publication statusPublished - 2016

Research programs

  • EMC MM-02-41-03

Cite this